A paper published online July 18 in the journal Science Report said scientists at the New York Stem Cell Foundation Institute have developed a new segmental tissue engineering (SATE) skeletal engineering technique. This technology enables researchers to create large-scale, personalized grafts that make it possible to treat patients with bone diseases or bone injuries through regenerative medicine. It is reported that the solution for the new study is to design smaller joints separately and then combine these joints. During the trial, the researchers designed grafts for rabbits with femoral defects. They first evaluated the size and shape of the rabbit femur defect by scanning the femur and then formed a transplant model. Next, divide the model into smaller parts and create custom brackets for each part. The researchers placed these nails into the bioreactor along with human induced pluripotent stem cell-derived mesoderm progenitors. It is understood that the bioreactor is specifically designed to accommodate bone grafts of various sizes to ensure uniform tissue development in the graft. Once the cells are integrated into the scaffold, the researchers will use biocompatible bone cements or other orthopedic devices to combine the segments of the bone graft into a whole, mechanically stable graft. Participants in the study said that SATE is a standardized, universal technology that is easy to implement, allowing bioengineered bone grafts to move faster from laboratory to clinical. Susan Solomon, CEO of the New York Stem Cell Institute, also said that there are millions of bone injuries caused by trauma, cancer, osteoporosis, osteonecrosis and other destructive diseases, and SATE technology is expected to improve these groups. life. Currently, the problem of bone defects due to disease and injury is increasing, and current major treatment options are the use of synthetic substitutes or the acquisition of bone grafts from other parts of the patient's body. However, these methods often cause immune rejection and fail to form the connective tissue or vasculature required for functional bone. In addition, bone marrow grafts produced by patient stem cells do not have these problems, but they also face the difficulty of producing implants of the precise size required by the patient. Therefore, the success of this technology is a great news for many patients with bone diseases and bone defects. NINGBO AUTRENDS INTERNATIONAL TRADE CO., LTD , https://www.metests.com